Which peptides are on FDA’s compounding safety-risk list?
Short answer
FDA’s page of bulk substances that may present significant safety risks in compounding lists 20 of the substances profiled here: AOD-9604, BPC-157, CJC-1295, Dihexa, Emideltide, Epitalon, GHK-Cu, GHRP-2, GHRP-6, Ipamorelin, Kisspeptin-10, KPV, LL-37, Melanotan II, MK-677, PEG-MGF, Selank, Semax, TB-500 and Thymosin alpha-1.1 Some are listed in category 2 and others among nominations that were withdrawn; each row quotes its profile.
Each entry below quotes its profile and links to the full answer there.
Listed 20
Not FDA-approved; FDA advised against adding it to the compounding list1,2,3
FDA’s compounding safety-risk page, current as of April 22, 2026, lists AOD-9604 among substances whose nominations were withdrawn, citing possible immune reactions, characterization problems and serious adverse events of unclear cause.1
Is AOD-9604 FDA-approved? · AOD-9604 vs Semaglutide · AOD-9604 vs Tesamorelin
Not an FDA-approved drug4
FDA’s compounding safety-risk page, last updated April 22, 2026, lists BPC-157 among substances whose nominations were withdrawn and says FDA lacks enough information to know whether it would cause harm in people.1
Is BPC-157 FDA-approved? · BPC-157 vs TB-500 · BPC-157 vs KPV
Unapproved new drug in cited enforcement record5
FDA’s compounding safety-risk page, current as of April 22, 2026, lists CJC-1295 among substances whose nominations were withdrawn, citing possible immune reactions, impurities and serious adverse events including increased heart rate.1
Is CJC-1295 FDA-approved? · CJC-1295 vs Ipamorelin · CJC-1295 vs Sermorelin
No FDA approval reported; FDA has no human exposure data for it1
FDA’s compounding safety-risk page, current as of April 22, 2026, lists dihexa acetate among bulk substances that were previously in category 2, for substances that may present significant safety risks, and whose nominations were withdrawn by the nominators.1
No FDA approval reported; on FDA’s compounding safety-risk list (category 2)1
FDA’s compounding safety-risk page, current as of April 22, 2026, lists GHRP-2 in category 2 under the interim policy for outsourcing facilities (section 503B) for certain routes since September 29, 2023, citing possible immune reactions from aggregation and impurities.1
Is GHRP-2 FDA-approved? · GHRP-2 vs GHRP-6 · GHRP-2 vs Ipamorelin
No FDA approval reported; on FDA’s compounding safety-risk list (category 2)1
FDA’s compounding safety-risk page, current as of April 22, 2026, lists GHRP-6 in category 2 under the interim policy for outsourcing facilities (section 503B) since September 29, 2023, citing possible immune reactions from aggregation and impurities.1
Is GHRP-6 FDA-approved? · GHRP-2 vs GHRP-6 · GHRP-6 vs Ipamorelin
Unapproved new drug in cited enforcement record5
FDA’s compounding safety-risk page, current as of April 22, 2026, lists ipamorelin acetate in category 2 under the 503B interim policy since September 29, 2023, and among substances whose nominations were withdrawn. It cites possible immune reactions and a published report of serious adverse events, including death.1
Is ipamorelin FDA-approved? · CJC-1295 vs Ipamorelin · Ipamorelin vs Sermorelin
No FDA approval reported; on FDA’s compounding safety-risk list1
FDA’s compounding safety-risk page, current as of April 22, 2026, lists cathelicidin LL-37 among bulk substances previously in category 2 whose nominations were withdrawn, citing possible immune reactions and characterization problems.1
No FDA approval reported; on FDA’s compounding safety-risk list1
FDA’s compounding safety-risk page, current as of April 22, 2026, lists Melanotan II among bulk substances previously in category 2 whose nominations were withdrawn, citing possible immune reactions from aggregation or impurities and the case reports above.1
Is Melanotan II FDA-approved? · Melanotan II vs Bremelanotide · Melanotan II vs Afamelanotide
MK-677
Not a peptide: a small molecule often looked up alongside peptides
No FDA approval reported; on FDA’s compounding safety-risk list (category 2)1,10
FDA’s compounding safety-risk page, current as of April 22, 2026, lists ibutamoren mesylate in category 2 under both interim compounding policies: for pharmacies (section 503A) since September 29, 2023, and for outsourcing facilities (section 503B) since December 29, 2022.1
Is MK-677 FDA-approved? · MK-677 vs Ipamorelin · MK-677 vs Sermorelin
No FDA approval reported; FDA has no human exposure data for it1,12
FDA’s compounding safety-risk page, current as of April 22, 2026, lists PEG-MGF among bulk substances previously in category 2, for substances that may present significant safety risks, whose nominations were withdrawn. It cites a possible significant risk of immune reactions and complexities with impurities and characterization.1
No FDA approval reported; FDA lists safety concerns from a withdrawn compounding nomination1
FDA’s compounding safety-risk page, current as of April 22, 2026, lists selank acetate among bulk drug substances that were in category 2 before their nominations were withdrawn, citing possible immune reactions from aggregation and impurities.1
Not an FDA-approved drug14
FDA’s compounding safety-risk page, last updated April 22, 2026, lists TB-500 among substances whose nominations were withdrawn and says FDA has not identified any human exposure data for it.1
Is TB-500 FDA-approved? · BPC-157 vs TB-500 · TB-500 vs Thymosin beta-4
Not FDA-approved; FDA advised against adding it to the compounding list1,3,15
FDA’s compounding safety-risk page, current as of April 22, 2026, lists thymosin alpha-1 among substances whose nominations were withdrawn, citing a possible significant risk of immune reactions and inadequate safety information.1
Is thymosin alpha-1 FDA-approved? · Thymosin alpha-1 vs Thymosin beta-4
Profiles that say the page does not list them 29
5-Amino-1MQ
Not a peptide: a small molecule often looked up alongside peptides
Cerebrolysin
Not a single peptide: a mixture often looked up alongside peptides
No FDA approval reported; studied in clinical trials1,32
FDA’s compounding safety-risk page, current as of April 22, 2026, does not list efinopegdutide.1
Is efinopegdutide FDA-approved? · Efinopegdutide vs Survodutide
In clinical trials; not FDA-approved1,33,34
FDA’s compounding safety-risk page, current as of April 22, 2026, does not list efpeglenatide.1
Is efpeglenatide FDA-approved? · Efpeglenatide vs Semaglutide
Follistatin-344
Not a peptide: a protein, larger than a peptide, often looked up alongside peptides
FDA’s compounding safety-risk page, current as of April 22, 2026, does not list hexarelin, either in category 2 or among withdrawn nominations.1
IGF-1 LR3
Not a peptide: a protein, larger than a peptide, often looked up alongside peptides
FDA approval withdrawn in 2009 at the maker’s request, not for safety or effectiveness53,54
FDA’s compounding safety-risk page, current as of April 22, 2026, does not list sermorelin, either in category 2 or among withdrawn nominations.1
Is sermorelin FDA-approved? · Sermorelin vs Tesamorelin · Ipamorelin vs Sermorelin
SLU-PP-332
Not a peptide: a small molecule often looked up alongside peptides
Tesofensine
Not a peptide: a small molecule often looked up alongside peptides
FDA’s compounding safety-risk page, current as of April 22, 2026, lists “thymosin beta-4, fragment (LKKTETQ), also known as TB-500” among withdrawn nominations with possible safety risks. It does not list full-length thymosin beta-4.1
Is thymosin beta-4 FDA-approved? · TB-500 vs Thymosin beta-4 · Thymosin alpha-1 vs Thymosin beta-4
Profiles that do not say whether the current page lists them 1
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Citations
Sources
Numbered markers in the text point here. Each link opens the original public record.
- 1Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 2FDA evaluation of AOD-9604-related bulk drug substances, November 5, 2024 (briefing document for the December 4, 2024 Pharmacy Compounding Advisory Committee) ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 3December 4, 2024 Meeting of the Pharmacy Compounding Advisory Committee · minutes ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 4FDA briefing document for BPC-157-related bulk drug substances ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 5Nicholasville Compounding Pharmacy and Its Owner Plead Guilty to Unlawful Distribution of Prescription Drugs ↗
U.S. Department of Justice · Official source · Source checked July 22, 2026
- 6FDA briefing document for emideltide (DSIP) (free base) and emideltide acetate ↗
U.S. Food and Drug Administration · Official source · Source checked July 29, 2026
- 7FDA briefing document for epitalon ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 8503A bulk drug substances under evaluation · GHK-Cu except injectable routes · updated May 14, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked July 22, 2026
- 9FDA evaluation of kisspeptin-10, July 5, 2024 (briefing document for the October 29, 2024 Pharmacy Compounding Advisory Committee) ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 10October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee · minutes ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 11FDA briefing document for KPV ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 12Bulk drug substances nominated for use in compounding under section 503A (categories 1 to 3) · updated May 14, 2026 ↗
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
- 13FDA briefing document for Semax ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 14FDA briefing document for TB-500 ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 15FDA evaluation of thymosin alpha-1-related bulk drug substances, November 15, 2024 (briefing document for the December 4, 2024 Pharmacy Compounding Advisory Committee) ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 165-Amino-1-methylquinolinium substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
- 17Drugs@FDA: TANZEUM (albiglutide), application 125431 · original approval April 15, 2014 ↗
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
- 18Apraglutide substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 19STARS Phase 3 Trial: Once-Weekly Apraglutide Reduces Parenteral Support in Short Bowel Syndrome-Intestinal Failure (2026) · PMID 42692160 ↗
Clinical Gastroenterology and Hepatology · Official source · Source checked November 15, 2026
- 20Avexitide acetate substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 21PREVENT: A Randomized, Placebo-controlled Crossover Trial of Avexitide for Treatment of Postbariatric Hypoglycemia (2021) · PMID 33616643 ↗
The Journal of Clinical Endocrinology & Metabolism · Official source · Source checked November 15, 2026
- 22Efficacy and safety of avexitide for treatment of hypoglycemia following bariatric and other upper gastrointestinal surgeries: a phase 2b study (2026) · PMID 42744082 ↗
Metabolism: Clinical and Experimental · Official source · Source checked November 15, 2026
- 23Aviptadil substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 24Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial (2023) · PMID 37348524 ↗
The Lancet Respiratory Medicine · Official source · Source checked November 15, 2026
- 25Cerebrolysin substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
- 26Cibinetide (ARA 290) substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 27Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain (2017) · PMID 28475703 ↗
Investigative Ophthalmology & Visual Science · Official source · Source checked November 15, 2026
- 28Cotadutide substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 29Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study (2021) · PMID 34016612 ↗
Diabetes Care · Official source · Source checked November 15, 2026
- 30Drugs@FDA: ZEGALOGUE (dasiglucagon hydrochloride), NDA 214231 · original approval March 22, 2021 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 31ZEGALOGUE (dasiglucagon) injection · SPL version 3 · published 2026-06-17 ↗
DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026
- 32Efinopegdutide substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
- 33Efpeglenatide substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
- 34ClinicalTrials.gov record NCT07379333 · retained source version 2026-05-13:c599578eaa8d429e0152e13caf981fed9266ac8441a80524f20f68e1f1aaac63 ↗
ClinicalTrials.gov · Official source · Source checked November 16, 2026
- 35Eloralintide substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 36Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial (2025) · PMID 41207310 ↗
The Lancet · Official source · Source checked November 15, 2026
- 37Drugs@FDA: FUZEON (enfuvirtide), NDA 021481 · original approval March 13, 2003 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 38Follistatin (activin-binding protein) substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
- 39Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging (2017) · PMID 28340339 ↗
Cell · Official source · Source checked November 16, 2026
- 40Glepaglutide substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 41Glepaglutide, a Long-Acting Glucagon-like Peptide-2 Analogue, Reduces Parenteral Support in Patients With Short Bowel Syndrome: A Phase 3 Randomized Controlled Trial (2025) · PMID 39708985 ↗
Gastroenterology · Official source · Source checked November 15, 2026
- 42Drugs@FDA: FACTREL (gonadorelin hydrochloride), NDA 018123 · original approval September 30, 1982 ↗
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
- 43Drugs@FDA: LUTREPULSE KIT (gonadorelin acetate), NDA 019687 · original approval October 10, 1989 ↗
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
- 44Examorelin (hexarelin) substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 45Humanin substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
- 46Long-(Arg3) insulin-like growth factor-I (IGF-1 LR3) substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
- 47Larazotide substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 48Larazotide acetate for persistent symptoms of celiac disease despite a gluten-free diet: a randomized controlled trial (2015) · PMID 25683116 ↗
Gastroenterology · Official source · Source checked November 15, 2026
- 49Janssen Pharmaceuticals, Inc., et al.; Withdrawal of Approval of 16 New Drug Applications (May 14, 2020) · FR Doc. 2020-10367 ↗
Federal Register · Official source · Source checked November 15, 2026
- 50Drugs@FDA: NATRECOR (nesiritide), NDA 020920 · original approval August 10, 2001 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 51Takeda Pharmaceuticals U.S.A., Inc.; Withdrawal of Approval of a New Drug Application for OMONTYS (peginesatide) Injection (February 13, 2019) · FR Doc. 2019-02146 ↗
Federal Register · Official source · Source checked November 16, 2026
- 52Drugs@FDA: OMONTYS (peginesatide acetate), NDA 202799 · original approval March 27, 2012 ↗
U.S. Food and Drug Administration · Official source · Source checked November 16, 2026
- 53Determination That GEREF (Sermorelin Acetate) Injection Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness (March 4, 2013) · FR Doc. 2013-04827 ↗
Federal Register · Official source · Source checked November 15, 2026
- 54Drugs@FDA: GEREF (sermorelin acetate), NDA 020443 · original approval September 26, 1997 ↗
U.S. Food and Drug Administration · Official source · Source checked November 15, 2026
- 55SLU-PP-332 (4-hydroxybenzoic acid 2-(2-naphthalenylmethylene)hydrazide) substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
- 56Tesofensine substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
- 57Thymopentin substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 16, 2026
- 58Thymosin beta-4 substance identity record ↗
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
- 59Weekly subcutaneous VK2735, a GIP/GLP-1 receptor dual agonist, for weight management: phase 2, randomized, 13-week VENTURE study (2026) · PMID 41508550 ↗
Obesity · Official source · Source checked November 16, 2026
- 60ClinicalTrials.gov record NCT07868835 · retained source version 2026-11-16:754cc17245a18215ce0d3940312a9a7ada00032d9098c9032f6a189cf2f02123 ↗
ClinicalTrials.gov · Official source · Source checked November 16, 2026
- 61FDA briefing document for MOTS-c ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 62HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026